Back Login to subscribe 🔔 Set Alert

BMY Bristol-Myers Squibb Co.

15 min delay

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	Arcus Biosciences Enters Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb; Will Supply Casdatifan, Its Investigational Small-Molecule HIF-2a Inhibitor	65.52%
	SystImmune And Bristol Myers Squibb Announce Sichuan Biokin Reports Results From Prespecified Interim Analyses Of Two Phase 3 Studies Evaluating Izalontamab Brengitecan	88.49%
	Why Is Replimune Stock Gaining Monday?	64.62%
	Full Transcript: Bristol-Myers Squibb Q1 2026 Earnings Call	61.59%
	Bristol Myers Squibb Says FDA Accepts Snda For Camzyos As Potential Treatment For Adolescents With Symptomatic oHCM; PDUFA Date Set September 30	80.54%
	Bristol Myers Squibb Announces European Commission Approval Of Opdivo In Combination With Doxorubicin, Vinblastine And Dacarbazine For The Treatment Of Adult And Adolescent Patients 12 Years Of Age And Older With Previously Untreated Stage III Or IV Classical Hodgkin Lymphoma	85.04%
	Wall Street's Most Accurate Analysts Give Their Take On 3 Healthcare Stocks Delivering High-Dividend Yields	82.89%
	Bistol Myers Squibb Announces Results From Its Phase 3 SUCCESSOR-2 Trial Of CELMoD Mezigdomide In Combination With Carfilzomib And Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma; Results Showed MeziKd Demonstrated Clinically Meaningful And Statistically Significant Improvement	95.42%
	Anthropic And OpenAI--Building Different Competitive Advantages	84.94%
	Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery	94.33%

1
2
3
›